Found: 6
Select item for more details and to access through your institution.
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
- Published in:
- European Heart Journal, 2023, v. 44, n. 31, p. 2982, doi. 10.1093/eurheartj/ehad344
- By:
- Publication type:
- Article
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 7, p. 1539, doi. 10.1002/ejhf.3269
- By:
- Publication type:
- Article
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 912, doi. 10.1002/ejhf.3184
- By:
- Publication type:
- Article
Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 8, p. 1396, doi. 10.1002/ejhf.2957
- By:
- Publication type:
- Article
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 7, p. 981, doi. 10.1002/ejhf.2909
- By:
- Publication type:
- Article
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
- Published in:
- Journal of the American Heart Association, 2024, v. 13, n. 5, p. 1, doi. 10.1161/JAHA.123.032279
- By:
- Publication type:
- Article